" /> Vilobelimab - CISMeF





Preferred Label : Vilobelimab;

NCIt definition : A monoclonal antibody targeting the human complement factor C5a, with potential anti-inflammatory and immunomodulating activities. Upon administration, vilobelimab specifically targets and binds to C5a. This prevents the binding of C5a to its receptor C5a receptor (C5aR) and prevents C5a/C5aR-mediated pro-inflammatory signaling, thereby reducing inflammation and tissue and organ damage. C5a, a factor in the complement cascade, plays important roles in inflammation and immunity. C5aR is expressed on multiple cell types including mast cells, phagocytes, bronchial and alveolar epithelial cells, hepatocytes, astrocytes and vascular endothelial cells.;

UNII : F5T0RF9ZJA;

CAS number : 2161337-20-6; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2161337-20-6 alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo G-SRS /a ;

Molecule name : IFX-1; IFX 1;

NCI Metathesaurus CUI : CL1406725;

Details


Keyword's position in hierarchy(ies) : arborescence

You can consult :


Nous contacter.
21/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.